Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.86%-0.69 ppBiotechnology2.29%-0.52 ppLife Sciences Tools & Services1.59%-0.39 ppManaged Health Care2.25%-0.32 ppHealth Care Services0.65%-0.29 ppHealth Care Equipment2.84%-0.04 ppHealth Care Facilities0.21%-0.02 ppHealth Care Supplies0.14%+0.02 ppHealth Care Distributors0.43%+0.02 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.29%
Industry change · 12M
-0.52 pp
Biotechnology · contribution
-0.520 pp
Company participation
63%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Nov 2023 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $251.4bn | 0.784% | -0.043 pp | -0.184 pp | -8.1% | Yes |
| Moderna → MRNA | United States | $29.6bn | 0.092% | -0.045 pp | -0.137 pp | -55.8% | No |
| Gilead Sciences → GILD | United States | $95.4bn | 0.298% | -0.006 pp | -0.076 pp | -9.5% | Yes |
| Amgen → AMGN | United States | $144.3bn | 0.450% | +0.013 pp | -0.069 pp | -2.6% | Yes |
| Biogen → BIIB | United States | $33.9bn | 0.106% | -0.018 pp | -0.043 pp | -23.3% | No |
| Incyte → INCY | United States | $12.2bn | 0.038% | -0.008 pp | -0.022 pp | -31.8% | No |
| Vertex Pharmaceuticals → VRTX | United States | $91.4bn | 0.285% | -0.001 pp | +0.009 pp | +12.1% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $77.4bn | 0.241% | -0.006 pp | +0.002 pp | +9.6% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.